Dyadic Reports Q3 2026 Financial Results
News related to:Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions · 2 min read
JUPITER, Fla., Oct. 30, 2026 /CourierPR/ -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions, a global biotechnology company focused on the scalable production of high-value, precision-engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended September 30, 2026, and host a corporate update conference call on Thursday, November 12, 2026.
The conference call will take place at 5:00 p.m. Eastern Time and can be accessed via the following numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274. The conference ID for the call is 13761286. An archived version of the webcast will be available within 24 hours after the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
The financial results for the quarter ended September 30, 2026, will be reported, and the company will provide an update on its research projects, third-party collaborations, and the availability of necessary funding. Dyadic will also discuss the progress of its clinical trial and its interest in its protein production platforms.
This announcement is significant as it provides investors and the public with crucial financial information and updates on the company's operations. The upcoming conference call will offer a platform for Dyadic to engage with stakeholders and address any questions or concerns they may have regarding the company's financial performance and future prospects.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
The Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic's Form 10-K and Form 10-Q filings, contain forward-looking statements. These statements reflect Dyadic's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of its clinical trial and interest in its protein production platforms, its research projects, and third-party collaborations, as well as the availability of necessary funding.
Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events, or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.